MONTREAL, Jan. 13 /CNW Telbec/ - Akela Pharma Inc. (TSX: “AKL”), a drug development company focused on developing therapies for the inhalation and pain markets, today announced that it has achieved the 3rd milestone in a series of three Fentanyl TAIFUN(R) Phase 3 study related milestones to be paid by Janssen Pharmaceutica NV.
